• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Praxis Precision Medicines (PRAX)

Common Shares
Sell: $296.00|Buy: $340.00|Change: 7.56 (-2.48%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized bya neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Address

One Broadway, 16th Floor
Cambridge
MA
USA
02142

Telephone

+1 617 300-8460

Website

https://www.praxismedicines.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Praxis Precision Medicines Inc Third Quarter Earnings Results for 20262026-11-05T08:00:00
Praxis Precision Medicines Inc Second Quarter Earnings Conference Call for 20262026-08-04T08:30:00
Praxis Precision Medicines Inc Second Quarter Earnings Results for 20262026-08-04T00:00:00
Praxis Precision Medicines Inc Annual General Meeting for 20262026-06-26T09:00:00
Praxis Precision Medicines Inc First Quarter Earnings Results for 20262026-05-01T00:00:00
Praxis Precision Medicines Inc Annual Report for 20252026-02-27T00:00:00

Previous key dates

NameKey Date
HCW with Praxis Medicines, Inc. (PRAX) - Deep Dive into Praxis’ Ulixacaltamide Data2025-11-24T13:00:00
Jefferies Global Healthcare Conference2025-11-18T13:30:00
Guggenheim Securities Inaugural Healthcare Innovation Conference2025-11-10T09:30:00
Praxis Precision Medicines Inc Third Quarter Earnings Results for 20252025-11-05T08:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-10T08:30:00
Virtual Fireside Chat with Praxis Precision Medicines Inc (PRAX)2025-08-07T11:00:00
Praxis Precision Medicines Inc Second Quarter Earnings Conference Call for 20252025-08-04T08:30:00
Praxis Precision Medicines Inc Second Quarter Earnings Result for 20252025-08-04T00:00:00
Praxis Precision Medicines Inc Annual General Meeting for 20252025-06-26T09:00:00
Praxis Precision Medicines Inc First Quarter Earnings Results for 20252025-05-02T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T11:00:00
UBS Virtual CNS Day2025-03-17T09:30:00
Barclays 27th Annual Global Healthcare Conference2025-03-12T14:30:00
Leerink Partners Global Healthcare Conference2025-03-10T15:40:00
45th Annual TD Cowen Health Care Conference2025-03-05T09:10:00
Praxis Precision Medicines Inc Annual Report for 20242025-02-28T00:00:00
Oppenheimer 35th Annual Healthcare Life Sciences Conference2025-02-11T11:20:00
Guggenheim Securities SMID Cap Biotechnology Conference2025-02-06T14:30:00
J.P. Morgan Healthcare Conference2025-01-15T14:15:00
Oppenheimer Movers in Rare Disease Summit2024-12-12T14:00:00
Piper Sandler 36th Annual Healthcare Conference2024-12-04T14:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.